Altamira Therapeutics (CYTO)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-2.89%)
Updated Nov 6, 2024 03:31 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYTO 0.51 -0.02(-2.89%)
Will CYTO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CYTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTO
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now
CYTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CYTO
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Altamira Therapeutics Faces Nasdaq Delisting
Altamira Therapeutics receives Nasdaq non-compliance letter
Altamira Therapeutics provides update on Nasdaq listing
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray